Advertisement bioCSL secures worldwide rights to commercialize BioCryst' influenza treatment Rapivab - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

bioCSL secures worldwide rights to commercialize BioCryst’ influenza treatment Rapivab

BioCryst Pharmaceuticals has licensed worldwide rights to commercialize influenza treatment Rapivab (peramivir injection) to Australian biopharmaceutical firm CSL.

Rapivab is an intravenous (IV) treatment indicated in the US for acute uncomplicated influenza in adults aged 18 years and older.

bioCSL general manager and senior vice-president Dr John Anderson said: "Rapivab is a specialty pharmaceutical that addresses an unmet medical need for the treatment of acute influenza in the hospital emergency room setting."

Under the deal, CSL’s subsidiary bioCSL has secured worldwide rights to commercialize Rapivab, with the exception of Japan, Korea, Taiwan and Israel. bioCSL specializes in influenza prevention through the supply of seasonal and pandemic influenza vaccine to global markets.

The deal will see BioCryst retain all rights to pursue pandemic stockpiling orders for Rapivab from the US government, while bioCSL will be responsible for government stockpiling outside the US.

Currently, the drug is licensed for use in Japan and Korea, and is the first and only approved intravenous influenza treatment in the world.

BioCryst will secure an upfront payment of $33.7m from bioCSL, and may receive up to $12m in additional payments related to the successful achievement of certain regulatory milestones.

In addition, BioCryst will get tiered royalties that are contingent upon certain net sales thresholds in the US and the rest of the world, as well as a percentage of proceeds from government stockpiling purchases outside the US.

Furthermore, bioCSL will buy existing and in-process inventory of Rapivab for treatment of influenza patients in upcoming flu seasons.